(19) World Intellectual Property Organization International Bureau

(43) International Publication Date 14 July 2005 (14.07.2005)

•





PCT

(10) International Publication Number WO 2005/063218 A2

(51) International Patent Classification7:

A61K 31/00

(21) International Application Number:

PCT/EP2004/014645

(22) International Filing Date:

22 December 2004 (22.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/532,334

23 December 2003 (23.12.2003) U

- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ZANNOU, Erika, Aina [FR/US]; 303 Timber Oaks Road, Edison, NJ 08820 (US). BATEMAN, Simon, David [GB/US]; 4 Farrington Lane, Randolph, NJ 07869 (US). PUDIPEDDI, Madhusudhan [IN/US]; 51 Calvert Avenue East, Edison, NJ 08826 (US). ROYCE, Alan, Edward [US/US]; RR 4 Box 9LE, Saylorsburg, PA 18353 (US). SERAJUDDIN, Abu,

T., M. [US/US]; 172-11 35 Avenue, Flushing, Queens, NY 11358 (US).

- (74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATES

(57) Abstract: A pharmaceutical formulation comprising an oral dosage form containing a bisphosphonic acid or a salt thereof and an inactive ingredient selected from: an ester of a medium chain fatty acid, or a lipophilic polyethylene glycol ester, said inactive ingredient having a hydrophilic lipophilic balance (HLB) of from about 1 to about 30.